Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00858871




Registration number
NCT00858871
Ethics application status
Date submitted
9/03/2009
Date registered
10/03/2009
Date last updated
17/10/2016

Titles & IDs
Public title
First Line Hepato Cellular Carcinoma (HCC)
Scientific title
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Secondary ID [1] 0 0
EUDRACT # 2008-003533-24
Secondary ID [2] 0 0
CA182-033
Universal Trial Number (UTN)
Trial acronym
BRISK FL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepato Cellular Carcinoma (HCC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Brivanib
Treatment: Drugs - Placebo
Treatment: Drugs - Sorafenib
Treatment: Drugs - Placebo

Active comparator: Brivanib -

Active comparator: Sorafenib -


Treatment: Drugs: Brivanib
Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity

Treatment: Drugs: Placebo
Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity

Treatment: Drugs: Sorafenib
Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity

Treatment: Drugs: Placebo
Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment
Timepoint [1] 0 0
Survival will be assessed continuously
Secondary outcome [1] 0 0
To compare the time to progression (TTP) (investigator assessed using modified RECIST criteria for HCC
Timepoint [1] 0 0
Every 6 weeks
Secondary outcome [2] 0 0
To compare the investigator assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST criteria for HCC
Timepoint [2] 0 0
Every 6 weeks
Secondary outcome [3] 0 0
To determine duration of response, duration of disease control, and time to response (TTR)
Timepoint [3] 0 0
Every 6 weeks
Secondary outcome [4] 0 0
To assess the safety profile of brivanib and sorafenib
Timepoint [4] 0 0
Every 6 weeks
Secondary outcome [5] 0 0
To explore PK and exposure-response in the study population
Timepoint [5] 0 0
Every 6 weeks
Secondary outcome [6] 0 0
To compare time to symptomatic progression
Timepoint [6] 0 0
Every 6 weeks
Secondary outcome [7] 0 0
To compare health-related quality of life
Timepoint [7] 0 0
Every 6 weeks

Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.



* Histologic or cytologic confirmed diagnosis of HCC.
* Advanced HCC: disease not eligible for surgical and/or locoregional therapies OR progressive disease after surgical and/or locoregional therapies
* Child-Pugh Class A
* ECOG performance status 0-1
* Adequate hematologic, hepatic, and renal function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior use of any systemic anti-cancer chemotherapy, immunotherapy or molecular targeted agents for HCC
* History of active cardiac disease
* Thrombotic or embolic events within the past 6 months (except HCC tumor thrombus)
* Any other hemorrhage/bleeding event >= CTCAE Grade 3 within 8 weeks except for esophageal or gastric varices
* Inability to swallow tablets or untreated malabsorption syndrome

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2013
Sample size
Target
Accrual to date
Final
1714
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Local Institution - Camperdown
Recruitment hospital [2] 0 0
Local Institution - Concord
Recruitment hospital [3] 0 0
Local Institution - Westmead Nsw
Recruitment hospital [4] 0 0
Local Institution - Parkville
Recruitment hospital [5] 0 0
Local Institution - Prahan
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2145 - Westmead Nsw
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
3004 - Prahan
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Argentina
State/province [11] 0 0
Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Santa Fe
Country [13] 0 0
Belgium
State/province [13] 0 0
Liege
Country [14] 0 0
Brazil
State/province [14] 0 0
Bahia
Country [15] 0 0
Brazil
State/province [15] 0 0
Ceara
Country [16] 0 0
Brazil
State/province [16] 0 0
Goias
Country [17] 0 0
Brazil
State/province [17] 0 0
Minas Gerais
Country [18] 0 0
Brazil
State/province [18] 0 0
Parana
Country [19] 0 0
Brazil
State/province [19] 0 0
Rio Grande do Sul
Country [20] 0 0
Brazil
State/province [20] 0 0
Rio Grande Do Sul
Country [21] 0 0
Brazil
State/province [21] 0 0
Sao Paulo
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
British Columbia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
China
State/province [27] 0 0
Chongqing
Country [28] 0 0
China
State/province [28] 0 0
Guangdong
Country [29] 0 0
China
State/province [29] 0 0
Guangxi
Country [30] 0 0
China
State/province [30] 0 0
Hubei
Country [31] 0 0
China
State/province [31] 0 0
Hunan
Country [32] 0 0
China
State/province [32] 0 0
Jiangsu
Country [33] 0 0
China
State/province [33] 0 0
Liaoning
Country [34] 0 0
China
State/province [34] 0 0
Shaanxi
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
China
State/province [36] 0 0
Sichuan
Country [37] 0 0
China
State/province [37] 0 0
Zhejiang
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Brno
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Prague 5
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Praha 2
Country [41] 0 0
France
State/province [41] 0 0
Bordeaux
Country [42] 0 0
France
State/province [42] 0 0
Clichy Cedex
Country [43] 0 0
France
State/province [43] 0 0
Creteil Cedex
Country [44] 0 0
France
State/province [44] 0 0
Grenoble Cedex 09
Country [45] 0 0
France
State/province [45] 0 0
Lille
Country [46] 0 0
France
State/province [46] 0 0
Lyon Cedex 04
Country [47] 0 0
France
State/province [47] 0 0
Marseille Cedex 05
Country [48] 0 0
France
State/province [48] 0 0
Marseille Cedex 9
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Rennes
Country [51] 0 0
France
State/province [51] 0 0
Vandoeuvre Cedex
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Halle
Country [54] 0 0
Germany
State/province [54] 0 0
Hamburg
Country [55] 0 0
Germany
State/province [55] 0 0
Magdeburg
Country [56] 0 0
Germany
State/province [56] 0 0
Ulm
Country [57] 0 0
Hong Kong
State/province [57] 0 0
Hong Kong
Country [58] 0 0
Hong Kong
State/province [58] 0 0
Shatin
Country [59] 0 0
India
State/province [59] 0 0
Andhra Pradesh
Country [60] 0 0
India
State/province [60] 0 0
Kerala
Country [61] 0 0
India
State/province [61] 0 0
Maharashtra
Country [62] 0 0
India
State/province [62] 0 0
Ahmedabad
Country [63] 0 0
India
State/province [63] 0 0
Chennai
Country [64] 0 0
India
State/province [64] 0 0
Coimbatore
Country [65] 0 0
India
State/province [65] 0 0
Hyderabad
Country [66] 0 0
India
State/province [66] 0 0
Kolkata
Country [67] 0 0
India
State/province [67] 0 0
Mumbai
Country [68] 0 0
India
State/province [68] 0 0
New Delhi
Country [69] 0 0
Italy
State/province [69] 0 0
Milano
Country [70] 0 0
Italy
State/province [70] 0 0
Napoli
Country [71] 0 0
Italy
State/province [71] 0 0
Pisa
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
Torrette -Ancona
Country [74] 0 0
Japan
State/province [74] 0 0
Chiba
Country [75] 0 0
Japan
State/province [75] 0 0
Hokkaido
Country [76] 0 0
Japan
State/province [76] 0 0
Ishikawa
Country [77] 0 0
Japan
State/province [77] 0 0
Kanagawa
Country [78] 0 0
Japan
State/province [78] 0 0
MIE
Country [79] 0 0
Japan
State/province [79] 0 0
Okayama
Country [80] 0 0
Japan
State/province [80] 0 0
Osaka
Country [81] 0 0
Japan
State/province [81] 0 0
Shizuoka
Country [82] 0 0
Japan
State/province [82] 0 0
Tokyo
Country [83] 0 0
Japan
State/province [83] 0 0
Yamaguchi
Country [84] 0 0
Japan
State/province [84] 0 0
Nishinomiya-shi
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Busan
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Daegu
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Gyeonggi-do
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Kyunggi-do
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Seoul
Country [90] 0 0
Mexico
State/province [90] 0 0
Distrito Federal
Country [91] 0 0
Mexico
State/province [91] 0 0
Nuevo Leon
Country [92] 0 0
Mexico
State/province [92] 0 0
Aguascalientes
Country [93] 0 0
Poland
State/province [93] 0 0
Gdansk
Country [94] 0 0
Poland
State/province [94] 0 0
Gliwice
Country [95] 0 0
Poland
State/province [95] 0 0
Krakow
Country [96] 0 0
Poland
State/province [96] 0 0
Warszawa
Country [97] 0 0
Puerto Rico
State/province [97] 0 0
San Juan
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Moscow
Country [99] 0 0
South Africa
State/province [99] 0 0
Gauteng
Country [100] 0 0
South Africa
State/province [100] 0 0
Kwa Zulu Natal
Country [101] 0 0
South Africa
State/province [101] 0 0
Western Cape
Country [102] 0 0
Spain
State/province [102] 0 0
A Coruna
Country [103] 0 0
Spain
State/province [103] 0 0
Alicante
Country [104] 0 0
Spain
State/province [104] 0 0
Barcelona
Country [105] 0 0
Sweden
State/province [105] 0 0
Stockholm
Country [106] 0 0
Sweden
State/province [106] 0 0
Uppsala
Country [107] 0 0
Taiwan
State/province [107] 0 0
Changhua
Country [108] 0 0
Taiwan
State/province [108] 0 0
Kaohsiung
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taichung
Country [110] 0 0
Taiwan
State/province [110] 0 0
Tainan R.O.C.
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taipei
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taoyuan
Country [113] 0 0
Thailand
State/province [113] 0 0
Bangkok
Country [114] 0 0
Turkey
State/province [114] 0 0
Ankara
Country [115] 0 0
Turkey
State/province [115] 0 0
Antalya
Country [116] 0 0
Turkey
State/province [116] 0 0
Istanbul
Country [117] 0 0
Turkey
State/province [117] 0 0
Izmir
Country [118] 0 0
Turkey
State/province [118] 0 0
Kayseri
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Avon
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Greater London
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Greater Manchester
Country [122] 0 0
United Kingdom
State/province [122] 0 0
West Midlands
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Trial website
https://clinicaltrials.gov/study/NCT00858871
Trial related presentations / publications
Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol. 2021 Oct;75(4):879-887. doi: 10.1016/j.jhep.2021.05.015. Epub 2021 May 27.
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Avina J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00858871